Literature DB >> 3512872

The treatment of chancroid.

G P Schmid.   

Abstract

Since the treatment of chancroid was reviewed in 1982, the results of subsequent treatment trials have offered the clinician additional therapeutic choices as well as shorter courses of therapy. Erythromycin (500 mg four times a day for seven days) provides consistently effective treatment for cases acquired throughout the world, although erythromycin-resistant strains have been isolated in Singapore. Sulfamethoxazole and trimethoprim (800 mg/160 mg orally twice a day for seven days), ceftriaxone (250 mg intramuscularly one time), and amoxicillin/clavulanic acid (500 mg/125 mg orally three times a day for seven days) are also efficacious. There is, however, significant geographic variability in the susceptibility of Haemophilus ducreyi to sulfamethoxazole and trimethoprim, suggesting this combination may become increasingly less effective, and a lack of in-depth experience in the treatment of chancroid with ceftriaxone and amoxicillin/clavulanic acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512872

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  9 in total

Review 1.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 2.  Treatment of chancroid.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Isolation of anaerobes from bubo associated with chancroid.

Authors:  B Kumar; V K Sharma; V Bakaya; A Ayyagiri
Journal:  Genitourin Med       Date:  1991-02

4.  Sulphaphenazole, streptomycin and sulphaphenazole combination, trimethoprim, and erythromycin in the treatment of chancroid.

Authors:  B Kumar; V K Sharma; V Bakaya
Journal:  Genitourin Med       Date:  1990-04

5.  Comparison of the in vitro activities of various parenteral and oral antimicrobial agents against endemic Haemophilus ducreyi.

Authors:  K E Aldridge; C Cammarata; D H Martin
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.

Authors:  J S Knapp; A F Back; A F Babst; D Taylor; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid.

Authors:  L Bodhidatta; D N Taylor; A Chitwarakorn; K Kuvanont; P Echeverria
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

8.  Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.

Authors:  M Motley; S K Sarafian; J S Knapp; A A Zaidi; G Schmid
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 9.  Chancroid and Haemophilus ducreyi.

Authors:  S A Morse
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.